Prof. Mike Chan Takes Centre Stage at Landmark Cell Therapy Book Launch in Kunming, China

Two moments from the official launch of Cell Therapy and Healthy Longevity in Kunming, China: Academician Wei Qiming joins Prof. Mike Chan and chief co-editor Prof. Liu Baochi in the first photograph, while Academician Han Zhongchao appears with Prof. Chan and Prof. Liu in the second.

KUNMING, China (Sept 12, 2026) — Malaysian scientist Prof. Dato’ Sri Dr. Mike Chan joined leading Chinese medical experts in Kunming on Saturday for the official launch of Cell Therapy and Healthy Longevity, a major new Chinese-language medical monograph bringing together research and clinical perspectives from China and abroad.

Prof. Mike Chan, chairman of European Wellness Biomedical Group, is a chief co-editor and contributing author of the book alongside Prof. Liu Baochi of the Shanghai Public Health Clinical Center affiliated with Fudan University.

They were joined at the event by prominent medical figures and contributors, including Academician Prof. Wei Qiming, Academician Han Zhongchao, Liu Jinfeng and senior representatives from China’s medical, scientific and healthcare sectors.

The book was unveiled during the 2026 annual gathering of the Cell Therapy Industry and Clinical Research Branch under the National Association of Health Industry and Enterprise Management.

At the launch ceremony, Prof. Mike Chan and fellow representatives presented the newly published volume before an audience of physicians, researchers, academicians and healthcare industry leaders. Delegates photographed and recorded the moment as copies of the book were displayed onstage.

The launch marked the culmination of an extensive collaboration involving 36 experts, including contributors associated with 10 Chinese universities and several international medical and scientific organisations.

Published by Macao Science Publishing House, the monograph examines advances in cellular therapy, precision medicine, regenerative health and the extension of healthspan—the period of life spent in good health.

A Significant Meeting of Medical Minds

The conference brought together leading doctors, scientists and specialists in cell therapy, clinical research and regenerative medicine.

Day 1 — September 11, 2026

Prof. Liu Baochi, chief editor of Cell Therapy and Healthy Longevity and professor at the Shanghai Public Health Clinical Center affiliated with Fudan University, chairs an extensive committee meeting attended by distinguished guests Academician Wei Qiming and Prof. Dato’ Sri Dr. Mike Chan, chairman of European Wellness Biomedical Group and the book’s chief editor and contributing author.

Day 2 — September 12, 2026

Prof. Dato’ Sri Dr. Mike Chan, Academician Han Zhongchao and Academician Wei Qiming take centre stage as distinguished VIP speakers, joining leading medical experts to share insights on cell therapy, regenerative medicine and healthy longevity.

The launch was part of a three-day scientific program held in Kunming from September 11 to 13, 2026. Proceedings began with the annual working meeting of the Cell Therapy Industry and Clinical Research, followed by an expert discussion on standards for preparing and applying bone marrow platelet-rich plasma, known as BMPRP.

Prof. Liu praised Prof. Chan’s compelling lecture, which captivated the committee and impressed the experts with its depth of knowledge and international perspective.

Prof. Liu Baochi presented the branch’s 2026 progress report, reviewing its work and future priorities in cellular medicine and clinical research.

Prof. Mike Chan participated in the roundtable discussion alongside Prof. Liu Baochi, Prof. Liu Jinfeng, Prof. Wei Qiming and other medical and industry representatives. The session focused on professional collaboration, knowledge-sharing and the responsible movement of cellular technologies from research laboratories into clinical settings.

One presentation called on participants to remain committed to their founding mission while building upon earlier achievements—a message that reflected the meeting’s emphasis on scientific continuity, responsible innovation and long-term cooperation.

The main conference opened the following morning with addresses by senior representatives and the formal presentation of Cell Therapy and Healthy Longevity.

The scientific program subsequently covered regenerative and longevity medicine, autologous stem cells, BMPRP, engineered exosomes, precision medicine, automated cell manufacturing, immune-cell applications, clinical safety and regulatory oversight.

The event backdrop announces the 2026 annual gathering of the Cell Therapy Industry and Clinical Research and the official launch of Cell Therapy and Healthy Longevity in Kunming.

Prof Chan Calls for Medicine with a Conscience

Speaking during the conference discussions, Prof. Mike Chan said scientific progress must remain connected to the fundamental responsibility of medicine: improving and protecting life.

His comments brought an ethical and human dimension to a highly technical programme. While the conference examined sophisticated therapeutic technologies, Prof. Mike Chan reminded participants that medical advancement should ultimately be measured by its ability to serve patients.

He urged the participating doctors, scientists and institutions to work collectively and share their knowledge across national and professional boundaries.

“Let us work as one together,” he said. “We will learn more from each other.”

Prof. Mike Chan also spoke about the personal philosophy that has shaped his work in regenerative medicine.

“I am a Buddhist, so I have always believed that you generate good karma by saving lives and enriching life,” said Prof. Mike Chan. “That good karma will come back to you and your family in return.”

His remarks stressed that medical knowledge carries a moral responsibility. Scientific expertise, he suggested, should be applied not only to conditions that are easily managed, but also to difficult diseases and unmet medical needs.

Proud of his Chinese Heritage

Prof. Mike Chan also expressed pride in his Chinese heritage and his hope that China would play an increasingly influential role in the responsible development of cellular medicine.

Prof. Mike Chan shares insights on precision cellular therapy and healthy longevity during his presentation to medical and scientific experts in Kunming.

“I am proud to be Chinese, always,” he said. “At every conference around the world, whether it is in the United States, Japan or elsewhere, my first address to the audience is: ‘I am Chinese.’”

He encouraged the participants to work together as a unified professional community, share their knowledge and bring relevant international experience and technology into China.

Physicians, researchers and healthcare industry representatives attend the annual meeting of the Cell Therapy Industry and Clinical Research Branch, held in conjunction with the launch of Cell Therapy and Healthy Longevity.

Prof. Mike Chan’s participation in the book gives the publication a strong international dimension. His contribution connects Chinese clinical experience and university-led research with knowledge developed through the European tradition of biological and cellular medicine.

He has spent more than four decades working in cellular therapy, immunology, peptides, biological medicine and precision regenerative health. He has authored or co-authored more than 60 books and published extensively in scientific journals.

Through the European Wellness Biomedical Group, he has helped establish an international network of medical, research, education and wellness facilities focused on preventive, regenerative and longevity medicine.

Experts Discuss the Future of Cellular Medicine

The Kunming program brought together a wide range of specialists to examine both the possibilities and responsibilities associated with cellular medicine.

Academician Han Zhongchao addressed the need to build a collaborative innovation ecosystem for regenerative and longevity medicine.

Academician Prof. Wei Qiming discussed the clinical application of autologous stem cells, while Prof. Mike Chan presented on optimising healthy lifespan through stem-cell technology.

Prof. Liu Baochi spoke about the preparation and application of BMPRP. Other presentations examined cellular approaches to diabetes complicated by kidney disease, engineered exosomes in chronic prostatitis and the future relationship between precision medicine and cell therapy.

The afternoon sessions explored autologous adipose-derived components, immune-cell-assisted strategies for liver cancer, automated cell manufacturing and efforts to move cellular technologies from laboratory research into clinical use.

Further presentations addressed BMPRP research in diabetic foot management, standards for the clinical application of platelet-rich plasma, PRP in pain management and cellular approaches to declining ovarian function.

Clinical safety and regulation also formed an important part of the programme. One session examined safety oversight in cell and gene therapy research, including key considerations in applications to the United States Food and Drug Administration.

Another presentation explored how nutrition and lifestyle may affect the effectiveness and durability of cellular interventions.

A practical session on PRP and BMPRP preparation and surgical observation was scheduled for the final day.

Prof. Wei Qiming Praises Book’s Clinical Value

Academician Prof. Wei Qiming described Cell Therapy and Healthy Longevity as the result of more than a decade of writing, research and clinical experience.

Speaking in Mandarin at the launch, he said the book takes readers from basic scientific research through clinical studies and into the application of different cellular approaches.

Prof. Mike Chan presents autographed copies of Cell Therapy and Healthy Longevity to fellow doctors, researchers and conference delegates during the book’s official launch in Kunming, China.

“Readers will find detailed introductions ranging from basic research and clinical trials to the application of autologous stem cells, PRP and BMPRP in individual diseases,” he said.

Prof. Wei noted that the publication examines conditions including diabetes, Alzheimer’s disease, kidney disorders and arthritis.

“Every chapter is written in considerable detail, from theory and practice to the introduction of clinical cases,” said Prof. Wei Qiming. “The book represents the accumulated result of more than a decade of work and clinical practice, and serves as a very good summary.”

His assessment underlined one of the publication’s principal objectives: to provide a structured connection between scientific theory, clinical experience and the treatment questions encountered by medical practitioners.

International Cooperation at the Heart of the Launch

The formal presentations were accompanied by discussions and informal exchanges among participants.

Prof. Mike Chan was photographed meeting delegates, presenting copies of the book and exchanging views with representatives from the medical, research and healthcare industries.

He also joined participants for commemorative photographs and a celebratory gathering following the conference sessions.

These interactions reflected the wider purpose of the event: bringing together specialists from different institutions and disciplines to share experience and develop professional relationships.

Prof. Mike Chan also discussed difficult medical conditions for which patients and families continue to seek better answers. He drew particular attention to autism as a growing international concern and referred to efforts involving children from China seeking assessment or support in Malaysia and elsewhere.

Cellular interventions for autism remain experimental and require rigorous research, ethical oversight and compliance with medical regulations. His comments nevertheless reflected the urgency surrounding unmet medical needs and the importance of continued scientific investigation.

Prof. Mike Chan also spoke about his group’s work involving animals.

The observation supported his broader message that research into disease, ageing and biological repair can benefit from cooperation across medical, scientific and veterinary disciplines.

About Cell Therapy and Healthy Longevity

Cell Therapy and Healthy Longevity is a multidisciplinary medical monograph examining the science, preparation, delivery and potential clinical applications of cell-based medicine.

It brings together the work of 36 experts, including contributors associated with Fudan University, Southern University of Science and Technology, Naval Medical University, Nanchang University, Shandong University, Southwest Medical University, Hainan Medical University, Central South University, Shanghai Jiao Tong University and Soochow University.

Fudan University and its affiliated medical institutions have the strongest representation, with six participating experts: Liu Baochi, Chen Shanwen, Li Lei, Liu Li, Si Yanhui and Wang Hao.

The deputy editors are Wang Hao of Shanghai Medical College at Fudan University; Liu Jinfeng of the Second Medical Center of the PLA General Hospital; and Liu Li of Zhongshan Hospital affiliated with Fudan University.

The publication also includes perspectives from prominent scholars including Academician Shi Yufang, Academician Prof. Wei Qiming, Academician Han Zhongchao and Academician Wang Fusheng.

At the centre of the book is the concept that the human body contains a “biological treasury” of cells, signalling systems and natural repair mechanisms that may potentially be harnessed to support tissue regeneration and restore biological function.

The book pays particular attention to autologous cells—cells obtained from a patient’s own body—and bone marrow-derived nucleated and mononuclear cells involved in blood formation, immune regulation, biological signalling and tissue repair.

It examines ultrasound-guided cellular delivery and discusses areas of investigation including liver disease, diabetes, premature ovarian insufficiency, osteoarthritis, cartilage damage and immune or bone-marrow suppression following chemotherapy.

The publication also explores cancer immunotherapies such as CAR-T-cell therapy, CAR-NK-cell therapy and tumour-infiltrating lymphocyte therapy, together with gene therapy, oncolytic viruses and emerging forms of cellular engineering.

Its wider message is that longevity should not be measured solely by lifespan. The more meaningful objective is healthspan—the number of years during which a person remains physically capable, mentally active and functionally independent.

Cellular medicine is not presented as a promise of immortality or a universal cure. Instead, it is examined as an evolving field that requires scientific evidence, ethical practice, manufacturing quality, regulatory oversight and a sustained commitment to patient safety.

Published by Macao Science Publishing House in July 2026, Cell Therapy and Healthy Longevity carries the ISBN 978-99996-49-69-8.

*Medical note: Cell-based interventions differ considerably in their level of supporting evidence, regulatory status and approved clinical use. Patients should consult qualified medical specialists and carefully assess the evidence, risks and applicable regulations before considering treatment.